Other Posts
LARVOL is pleased to present a moderated discussion with top oncologists following ASCO's Annual Meeting 2021. In the video below, Dr. Eric Whitman, Dr. Allison Betof Warner, and Dr. Jason Luke discuss the practice-changing impact of ASCO presentations in melanoma.
On June 6, 2021, LARVOL hosted an Oncology Panel to discuss the top melanoma clinical trial abstracts presented during the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, held on June 4-8,2021. Dr. Eric Whitman from the Atlantic Health System Cancer Care moderated a discussion between Dr. Allison Betof Warner from Memorial Sloan Kettering Cancer Center and Dr. Jason Luke from University of Pittsburgh Medical Center.
The discussion covered ASCO abstract #9503 Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047), ASCO abstract #9502 Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma and ASCO Abstract #9506 CheckMate 067: 6.5-year outcomes inpatients (pts) with advanced melanoma.
Watch this video for the full discussion:
Our ASCO Panel Series covered six therapeutic areas including melanoma. Click below to read more about them and watch their video analysis.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
